Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Extended release of adenovirus from silica implants in vitro and in vivo.
Kangasniemi L, Koskinen M, Jokinen M, Toriseva M, Ala-Aho R, Kähäri VM, Jalonen H, Ylä-Herttuala S, Moilanen H, Stenman UH, Diaconu I, Kanerva A, Pesonen S, Hakkarainen T, Hemminki A. Kangasniemi L, et al. Among authors: diaconu i. Gene Ther. 2009 Jan;16(1):103-10. doi: 10.1038/gt.2008.142. Epub 2008 Aug 28. Gene Ther. 2009. PMID: 18754041
Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.
Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, Nokisalmi P, Raki M, Rajecki M, Guse K, Ranki T, Oksanen M, Holm SL, Haavisto E, Karioja-Kallio A, Laasonen L, Partanen K, Ugolini M, Helminen A, Karli E, Hannuksela P, Pesonen S, Joensuu T, Kanerva A, Hemminki A. Koski A, et al. Among authors: diaconu i. Mol Ther. 2010 Oct;18(10):1874-84. doi: 10.1038/mt.2010.161. Epub 2010 Jul 27. Mol Ther. 2010. PMID: 20664527 Free PMC article. Clinical Trial.
Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.
Cerullo V, Diaconu I, Kangasniemi L, Rajecki M, Escutenaire S, Koski A, Romano V, Rouvinen N, Tuuminen T, Laasonen L, Partanen K, Kauppinen S, Joensuu T, Oksanen M, Holm SL, Haavisto E, Karioja-Kallio A, Kanerva A, Pesonen S, Arstila PT, Hemminki A. Cerullo V, et al. Among authors: diaconu i. Mol Ther. 2011 Sep;19(9):1737-46. doi: 10.1038/mt.2011.113. Epub 2011 Jun 14. Mol Ther. 2011. PMID: 21673660 Free PMC article. Clinical Trial.
Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus.
Liikanen I, Monsurrò V, Ahtiainen L, Raki M, Hakkarainen T, Diaconu I, Escutenaire S, Hemminki O, Dias JD, Cerullo V, Kanerva A, Pesonen S, Marzioni D, Colombatti M, Hemminki A. Liikanen I, et al. Among authors: diaconu i. Mol Ther. 2011 Oct;19(10):1858-66. doi: 10.1038/mt.2011.144. Epub 2011 Jul 26. Mol Ther. 2011. PMID: 21792178 Free PMC article.
Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.
Liikanen I, Ahtiainen L, Hirvinen ML, Bramante S, Cerullo V, Nokisalmi P, Hemminki O, Diaconu I, Pesonen S, Koski A, Kangasniemi L, Pesonen SK, Oksanen M, Laasonen L, Partanen K, Joensuu T, Zhao F, Kanerva A, Hemminki A. Liikanen I, et al. Among authors: diaconu i. Mol Ther. 2013 Jun;21(6):1212-23. doi: 10.1038/mt.2013.51. Epub 2013 Apr 2. Mol Ther. 2013. PMID: 23546299 Free PMC article.
59 results